Prognostic Risk

Approximately 1 out of 4 patients has poor prognostic risk at the time of diagnosis1

  • 20% to 26% of patients with advanced RCC are poor risk at the time of the 1st-line treatment decision1*
*Percentage of poor-risk patients based on published analyses using the Database Consortium, International Kidney Cancer Working Group, Cleveland Clinic Foundation, French, and Memorial Sloan-Kettering Cancer Center risk models.1

Prognostic risk is a predictor of patient survival2,3

  • The NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer list prognostic systems that are used for risk stratification in the metastatic setting2-4
  • NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way
  • Evidence shows that prognostic risk is one of a number of factors to consider when managing advanced RCC2,3,5
 
 
REFERENCES
  1. Heng DYC, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141-148.
  2. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289-296.
  3. Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794-5799.
  4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kidney Cancer V.2.2019. © National Comprehensive Cancer Network, Inc 2018. All rights reserved. Accessed September 17, 2018. To view the most recent and complete version of the guideline, go online to www.nccn.org.
  5. Mekhail TM, Abou-Jawde RM, BouMerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23(4):832-841.